Australian TGA approves BeiGene's Brukinsa to treat patients with mantle cell lymphoma

BeiGene, a global, science─driven biotechnology company, announced that Brukinsa (zanubrutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have